Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "herniated" HDL, a common feature in diabetes

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Amigo, Nuria ^a,b   Mallol, Roger ^a,b   Heras, Mercedes ^b,c   Martinez Hervas, Sergio ^b,d   Blanco Vaca, Francisco ^b,e,f   Escola Gil, Joan Carles ^b,e,f   Plana, Nuria ^b,c   Yanes, Oscar ^a,b   Masana, Lluis ^b,c   Correig, Xavier ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

^e BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^f UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; FLUORESCENT DYE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDOLE DERIVATIVE; LIPID; MK-0524; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ATOMIC FORCE MICROSCOPY; CARDIOVASCULAR DISEASES; CHEMISTRY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; FEMALE; HUMAN; LIPID METABOLISM; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SURFACE PROPERTY; ULTRASTRUCTURE;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; FENOFIBRATE; FLUORESCENT DYES; HUMANS; INDOLES; LIPID METABOLISM; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROSCOPY, ATOMIC FORCE; MIDDLE AGED; NIACIN; SIMVASTATIN; SURFACE PROPERTIES; TRIGLYCERIDES;

EID: 84954513616     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19249     Document Type: Article

References (50)

1. Aguiree, F. et al. IDF Diabetes Atlas: 6th edn, http://www.idf.org/diabetesatlas (2013). (Date of access: 11/11/2015).
2. Chapman, M. J. et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 32, 1345-61 (2011).
3. Gordon, D. J. et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79, 8-15 (1989).
4. Barter, P. et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med. 357, 1301-1310 (2007).
5. Vergeer, M., Holleboom, A. G., Kastelein, J. J. P., Kuivenhoven, J. A. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis J. Lipid Res. 51, 2058-2073 (2010).
6. Rohatgi, A. et al. HDL Cholesterol Efflux Capacity and Incident Cardiovascular Events. N. Engl. J. Med. 371, 2383-2393 (2014).
7. Rader, D. J., Tall, A. R. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis Nat. Med. 18, 1344-6 (2012).
8. Heinecke, J. The not-so-simple HDL story: A new era for quantifying HDL and cardiovascular risk Nat. Med. 18, 1346-1347 (2012).
9. Kingwell, B. A., Chapman, M. J., Kontush, A., Miller, N. E. HDL-targeted therapies: progress, failures and future. Nat. Rev. Drug Discov. 13, 445-64 (2014).
10. Escolà-Gil, J. C., Cedó, L., Blanco-Vaca, F. High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong Expert Opin. Drug Discov. 9, 119-24 (2014).
11. Escolà-Gil, J. C., Rotllan, N., Julve, J., Blanco-Vaca, F. In vivo macrophage-specific RCT and antioxidant and antiinflammatory HDL activity measurements: New tools for predicting HDL atheroprotection. Atherosclerosis 206, 321-327 (2009).
12. deGoma, E. M., deGoma, R. L., Rader, D. J. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51, 2199-211 (2008).
13. Pirillo, A., Norata, G. D., Catapano, A. L. High-density lipoprotein subfractions-what the clinicians need to know. Cardiology 124, 116-25 (2013).
14. Stein, J. H., McBride, P. E. Should advanced lipoprotein testing be used in clinical practice Nat. Clin. Pract. Cardiovasc. Med. 3, 640-1 (2006).
15. Shen, B., Scanu, A., Kezdy, F. Structure of human serum lipoproteins inferred from compositional analysis. Proc. Natl. Acad. Sci. USA 74, 837-841 (1977).
16. Mazer, N. A., Giulianini, F., Paynter, N. P., Jordan, P., Mora, S. A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study. Clin. Chem. 59, 949-58 (2013).
17. Mallol, R. et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J. Lipid Res. 56, 737-746 (2015).
18. MacKey, R. H. et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 60, 508-516 (2012).
19. Mora, S. et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119, 931-939 (2009).
20. Qi, Y., Fan, J., Liu, J., Wang, W. Cholesterol-Overloaded HDL Particles Are Independently Associated With Progression of Carotid Atherosclerosis in a Cardiovascular Disease-Free Population: A Community-Based Cohort Study. J. Am. Coll. Cardiol. 65, 355-363 (2015).
21. Kumpula, L. S. et al. Reconsideration of hydrophobic lipid distributions in lipoprotein particles. Chem. Phys. Lipids 155, 57-62 (2008).
22. Yetukuri, L. et al. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J. Lipid Res. 51, 2341-2351 (2010).
23. Rosenson, R. S. et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 57, 392-410 (2011).
24. Hutchins, P., Ronsein, G. Quantification of HDL particle concentration by calibrated ion mobility analysis. Clin. Chem. 60, 1393-1401 (2014).
25. Krasnowska, E. K., Gratton, E., Parasassi, T. Prodan as a membrane surface fluorescence probe: partitioning between water and phospholipid phases. Biophys. J. 74, 1984-1993 (1998).
26. Krasnowska, E. K., Bagatolli, L. A., Gratton, E., Parasassi, T. Surface properties of cholesterol-containing membranes detected by Prodan fluorescence. Biochim. Biophys. Acta-Biomembr. 1511, 330-340 (2001).
27. Massey, J., Pownall, H. Surface properties of native human plasma lipoproteins and lipoprotein models. Biophys. J. 74, 869-878 (1998).
28. Ala-Korpela, M. et al. 1H NMR-based absolute quantitation of human lipoproteins and their lipid contents directly from plasma. J. Lipid Res. 35, 2292-2304 (1994).
29. Kontush, A., Chapman, M. J. Composition. In High-Density Lipoproteins 3-38 (John Wiley & Sons, Inc., 2011).
30. Kontush, A., Chapman, M. J. Heterogeneity. In High-Density Lipoproteins 39-58 (John Wiley & Sons, Inc., 2011).
31. Nobécourt, E. et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 48, 529-38 (2005).
32. Anderson, D., Nichols, A., Pan, S., Lindgren, F. High density lipoprotein distribution: resolution and determination of three major components in a normal population sample. Atherosclerosis 29, 161-179 (1978).
33. Blanche, P., Gong, E., Forte, T., Nichols, A. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim. Biophys. Acta 665, 408-419 (1981).
34. Chapman, M. J., Goldstein, S., Lagrange, D., Laplaud, P. M. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 22, 339-358 (1981).
35. Carlson, J. W., Jonas, A., Sligar, S. G. Imaging and manipulation of high-density lipoproteins. Biophys. J. 73, 1184-1189 (1997).
36. Feng, M. et al. Adsorption of High Density Lipoproteins (HDL) on Solid Surfaces. J. Colloid Interface Sci. 177, 364-371 (1996).
37. Ståhlman, M. et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim. Biophys. Acta 1831, 1609-17 (2013).
38. Camont, L. et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 33, 2715-23 (2013).
39. Gu, F. et al. Structures of discoidal high density lipoproteins: a combined computational-experimental approach. J. Biol. Chem. 285, 4652-65 (2010).
40. Edelstein, C., Kezdy, F., Scanu, A., Shen, B. Apolipoproteins and the structural organization of plasma lipoproteins: human plasma high density lipoprotein-3. J. Lipid Res. 20, 143-153 (1979).
41. Phillips, J. C., Wriggers, W., Li, Z., Jonas, A., Schulten, K. Predicting the structure of apolipoprotein A-I in reconstituted highdensity lipoprotein disks. Biophys. J. 73, 2337-46 (1997).
42. Tajima, S., Yokoyama, S., Yamamoto, A. Mechanism of action of lipoprotein lipase on triolein particles: effect of apolipoprotein C-II. J. Biochem. 96, 1753-1767 (1984).
43. Farbstein, D., Levy, A. P. HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther 10, 353-361 (2012).
44. Masana, L., et al. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients. Atherosclerosis 238, 213-219 (2015).
45. Kontush, A., Chapman, M. J. Why is HDL functionally deficient in type 2 diabetes Curr. Diab. Rep. 8, 51-59 (2008).
46. Kontush, A., Chapman, M. J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342-374 (2006).
47. Zerrad-Saadi, A. et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 29, 2169-75 (2009).
48. Schumaker, V. N., Puppione, D. L. Sequential flotation ultracentrifugation. Methods Enzymol 128, 155-170 (1986).
49. Mallol, R. et al. Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy. Anal. Bioanal. Chem. 402, 2407-2415 (2012).
50. Johnson Jr, C. Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications. Prog. Nucl. Magn. Reson. Spectrosc. 34, 203-256 (1999).